Sign in

TRAX on Nasdaq

First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics, Inc. is an American pharmaceutical preparations company based in San Diego.2 Its shares trade on Nasdaq under the symbol TRAX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerTRAX on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersSan Diego, United States2
  • Incorporated inDE3
  • Business address10770 Wateridge Circle, Suite 210, San Diego, Ca 921213
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI529900CGIGKN4R5RO9252
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 103556822

See how the biggest companies compare on our leaderboards

Corporate structure

First Tracks Biotherapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of First Tracks Biotherapeutics, Inc.

  • Sirenia Capital Management LP Filed SCHEDULE 13G on First Tracks Biotherapeutics, Inc., latest Aug 14, 2026
  • TCG Crossover GP II, LLC Filed SCHEDULE 13G on First Tracks Biotherapeutics, Inc., latest Aug 14, 2026
  • Affinity Asset Advisors, LLC Filed SCHEDULE 13G on First Tracks Biotherapeutics, Inc., latest Aug 13, 2026
  • FMR LLC Filed SCHEDULE 13G on First Tracks Biotherapeutics, Inc., latest Aug 6, 2026
  • BlackRock Filed SCHEDULE 13G on First Tracks Biotherapeutics, Inc., latest Jul 28, 2026
  • EcoR1 Capital, LLC Filed SCHEDULE 13G on First Tracks Biotherapeutics, Inc., latest Apr 22, 2026
  • First Tracks Biotherapeutics, Inc. San Diego, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led First Tracks Biotherapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel Faga2026–now

President

  1. Daniel Faga2026–now

Chief financial officer

  1. Ajim Tamboli2026–now
Board members and other officers (9)

Former names

  • Biopharma Company, Inc.Feb 6, 2026 to Feb 6, 20263

Timeline

  1. Oct 15, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure14
  2. Oct 13, 20268-K Regulation FD disclosure; Other events15
  3. Aug 12, 20268-K Results of operations16
  4. Jun 22, 20268-K Entered a material agreement17
  5. May 14, 20268-K Results of operations18
  6. Apr 20, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares19
  7. Apr 3, 20268-K Regulation FD disclosure20
  8. Apr 1, 2026New chief executive Daniel Faga becomes CEO4
  9. Oct 17, 2025Founded First Tracks Biotherapeutics, Inc. is founded2

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202621

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results16
  2. May 14, 2026Reported quarterly or annual results18

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

86 filings to the SEC since October 2021: 2 quarterly reports, 7 major events, 56 insider forms, 6 large holders, 15 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Oct 13, 20268-K EDGAR
  3. Sep 17, 20264 EDGAR
  4. Sep 4, 20264 EDGAR
  5. Sep 2, 2026144 EDGAR
  6. Aug 18, 20264 EDGAR
  7. Aug 18, 20264 EDGAR
  8. Aug 18, 20264 EDGAR
  9. Aug 14, 2026SCHEDULE 13G EDGAR
  10. Aug 14, 2026SCHEDULE 13G EDGAR
  11. Aug 13, 2026424B3 EDGAR
  12. Aug 13, 2026SCHEDULE 13G EDGAR
  13. Aug 12, 202610-Q EDGAR
  14. Aug 12, 20268-K EDGAR
  15. Aug 7, 20263/A EDGAR
  16. Aug 7, 20263/A EDGAR
  17. Aug 7, 20263/A EDGAR
  18. Aug 6, 2026SCHEDULE 13G EDGAR
  19. Aug 5, 20264 EDGAR
  20. Aug 5, 20264 EDGAR

The 86 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 0 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 2, 2026Ware J. AnthonyDirectorSale39,265$44.78$1.8MForm 4
Apr 20, 2026EcoR1 Capital, LLC10% ownerSale4,705,575$13.81$65.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
EcoR1 Capital, LLC3,174,519$63.9M3.2%New
TCG Crossover Management, LLC2,895,304$58.3M1.4%New
Fmr LLC2,054,127$41.3M0.0%New
Affinity Asset Advisors, LLC2,032,012$40.9M2.0%New
BlackRock, Inc.1,963,541$39.5M0.0%New
Trails Edge Capital Partners, LP1,514,000$30.5M4.8%New
Vanguard Capital Management LLC1,451,909$29.2M0.0%New
Jupiter Topco LLC1,091,464$22.0M0.0%New
Vestal Point Capital, LP1,013,000$20.4M0.5%New
Woodline Partners LP917,176$18.5M0.1%New
Sanofi821,917$16.5M3.1%New
Morgan Stanley781,534$15.7M0.0%New
683 Capital Management, LLC750,000$15.1M1.4%New
Adage Capital Partners Gp, L.l.c.729,000$14.7M0.0%New
Balyasny Asset Management L.P.714,948$14.4M0.0%New
Geode Capital Management, LLC702,087$14.1M0.0%New
Bank Of America Corp /de/647,962$13.0M0.0%New
Stempoint Capital LP622,723$12.5M2.2%New
Palo Alto Investors LP603,489$12.1M1.7%New
Sofinnova Investments, Inc.565,199$11.4M0.6%New
Vanguard Portfolio Management LLC546,992$11.0M0.0%New
Nantahala Capital Management, LLC500,000$10.1M0.3%New
Goldman Sachs Group Inc487,213$9.8M0.0%New
Point72 Asset Management, L.P.408,330$8.2M0.0%New
UBS Group AG310,886$6.3M0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How First Tracks Biotherapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARFirst Tracks Biotherapeutics, Inc.1
  • CIK0002091349
  • Employer ID (EIN)39-50032071
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address10770 Wateridge Circle, Suite 210, San Diego, CA 921211
  • Phone212-373-30001
  • Shares outstanding35,730,843 as of Aug 7, 202628
  • On EDGAR sinceFeb 6, 20261
  • Filings86 in all: 4 (35), 3 (12), 8-K (7), 4/A (6), SCHEDULE 13G (6), 3/A (3), 424B3 (3), 10-Q (2)1
    All 19 form types

    DRS (2), 10-12B (1), 10-12B/A (1), 144 (1), CERT (1), CORRESP (1), EFFECT (1), S-1 (1), S-8 (1), SEC STAFF ACTION (1), UPLOAD (1)

  • Latest filingsQuarterly report (10-Q) Aug 12, 2026
    Latest 8-K (8-K) Oct 15, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28